Market Overview

UPDATE: Canaccord Genuity Initiates Coverage on Lannett Company with Buy Rating, $7 PT

Related LCI
5 NYSE Healthcare Stocks With The Highest Operating Margin
Lannett Signs Definitive Agreement To Acquire Silarx Pharmaceuticals, Inc.

In a report published Friday, Canaccord Genuity initiated coverage on Lannett Company (NYSE: LCI) with a Buy rating and $7.00 price target.

Canaccord Genuity noted, “We are initiating coverage on Lannett Company (LCI) with a BUY-rating and $7 price target. We see an attractive 3- to 5-year growth story (36% EPS CAGR through 2017E) underpinned by LCI's vertically integrated pain management franchise (narcotics, controlled substances) that is differentiated and high barrier, as well as a robust pipeline with several large product opportunities that can drive P&L upside. LCI's fiscal 1Q results last night provided a solid start to the year and added confidence to fiscal 2013 guidance.”

Lannett Company closed on Thursday at $4.00.

Latest Ratings for LCI

Nov 2014Canaccord GenuityMaintainsBuy
Oct 2014OppenheimerMaintainsOutperform
Aug 2014OppenheimerMaintainsOutperform

View More Analyst Ratings for LCI
View the Latest Analyst Ratings

Posted-In: Canaccord GenuityAnalyst Color Initiation Analyst Ratings


Related Articles (LCI)

Around the Web, We're Loving...